A protein-based score shows promise but no immediate application for improving screening.
There is a continuing search for next-generation cardiovascular risk biomarkers or scores. Polygenic risk scores focus on the genome. The ability for large-scale measurement of proteins has led investigators to determine whether proteomics data can predict atherosclerotic cardiovascular disease (ASCVD) events.
In the current study, investigators leveraged plasma samples from 13,540 people aged 40–75 years in Iceland to develop and test the ability of a summary protein score to predict a first major ASCVD event (myocardial infarction, stroke, or coronary heart disease death). Events were identified from ICD codes generated from healthcare utilization in the Icelandic healthcare system. In all, 1507 people experienced an ASCVD event, with a me…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association